Evaluation of German Disease Management Programs (DMP)
Medical Netcare evaluates most DMP in Germany since the beginning of the statutory evaluation. All current programs - for the indications diabetes mellitus type 1 and type 2, coronary heart disease, breast cancer, COPD and bronchial asthma - are evaluated by MNC.
In-house Software Development
Quick response times
Fully Customisable Report Design
Rely on us
MNC at a glance
Health Care Management
The Medical Netcare GmbH (MNC) is a scientific Contract Research Organisation (CRO) and medium-sized company. Our focus lies on the health care market. We are working as evaluator and data analyst for health insurance companies, pharmaceutical companies or government institutions. We also offer custom solutions for data management in general.
At present, our customers include all current statutory health insurances of 3 of the 4 german unions (“BKK”, “IKK” and “vdek”), the Federal Joint Committee of physicians, dentists, psychotherapists, hospitals and health insurance companies in Germany (G-BA) and the Westfalen AG, a German oil company.
MNC currently employs staff in the fields of health management, medicine, natural sciences and humanities, economics and IT technology and maintains close collaborations with faculties, medical societies and associations.
MNC stands for the idea that all patients receive the health care that is optimally matched. To this end, it is necessary that the supply is linked at its best.
We support this networking between the suppliers, especially across sectors, and lead science and care practice to a dialogue. We provide assistance in overcoming barriers by customised solutions, which help to improve your collaborations. Meanwhile, we are always mindful to protect the privacy and security of your data.
We create the basis for meaningful evidence-based health care decisions with our scientific work. This can lead to a continual improvement in health care and prevention and - in the long run - to enhancements in public health.
The cooperation with each other as well as with our customers is characterized by trust, our orientation to the benefit of humanity and the delight in a continuous professional enhancement of standards in interdisciplinary and intersectoral collaboration.
The Medical Netcare GmbH was founded in 1999 by Dr. Christof Münscher and economist (Diplom-Volkswirt) Frank Potthoff. After several years of research, MNC attracted attention with its first publications. Between 2003 and 2007, various study results were published, including the in diabetology much acclaimed TEMPO®-study, the COMPACT®-study, awarded as one of the top 20 health economic works worldwide, the pharmacoeconomic analysis Phazit® and the Benchmark©-study.
Afterwards, the path led to the evaluation of the very young disease management programs - a project that is still running today and whose structured treatment has supplemented the conventional standard care comprehensively. A little later, MNC also evaluated an integrated care (IV) project of the AOK Rheinland (a german health insurance company), a project which aims in particular at better networking between the sectors of health care (e.g. family doctor, specialist, hospital) to improve the benefit of the patient: Settled family doctors or specialists working with inpatient facilities cooperate in the treatment of their patients and possibly even share a common budget. A total of 22 locally limited networks have been established and scientifically monitored by MNC.
Improvement in Patient Care
MNC dedicates itself entirely to the patient's benefit - in 2007, the next project started, which aimed directly at improving patient care: the Quality Assurance in dialyis treatment, for which MNC quarterly creates more than 700 individual reports for all dialysis facilities in Germany and provides a complete overview report to show the overall quality in dialysis treatment once a year. Since 2014, MNC also generates the nationwide benchmarking in dialysis treatment.
MNC has become a specialist for huge amounts of data. Each year, just for the evaluation of the six indications in DMP (DM1, DM2, CHD, breast cancer, asthma & COPD) around 25 million records flow to MNC. About 60% of these are medical documentations and 40% are patient characteristic data. MNC merges this data in a matching procedure.
For the indication with the most enrolled patients, diabetes mellitus type 2, the data of nearly 4 million patients is evaluated over a period of over 10 years in the current evaluation reports.